Centene vs Genmab

Centene (CNC), health care, and Genmab (GMAB), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Centene is worth $35.9B on the stock market and Genmab $32B: Centene is valued at 12% more. Centene trades at 24.9 times earnings and Genmab at 44.4; operating margins in their latest fiscal years were -3.91% and 28.6%. Over the past year Centene's share price has moved +102% and Genmab's +70.1%.

Key facts

Centene market value
$35.9B
Genmab market value
$32B
Centene P/E
24.9
Genmab P/E
44.4
Centene revenue
$194.8BFY to 2025-12-31
Genmab revenue
$3.7BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Centene vs Genmab: every measure side by side
Measure Centene Genmab
SectorHealth CareHealth Care
Country United States Denmark
Fiscal year ends2025-12-312025-12-31
Size
Market cap$35.9Bhigher$32Blower
Revenue$194.8Bhigher$3.7Blower
Earnings-$6.7Blower$963Mhigher
Employees61,100higher3,244lower
Total assets$76.7Bhigher$12.9Blower
Valuation
P/E24.9lower44.4higher
P/S0.2lower8.6higher
P/B1.6—
Dividend yield0.00%—
Profitability
Operating margin-3.91%lower28.6%higher
Balance sheet
Net assets$20Bhigher$5.8Blower
Total liabilities$56.7Bhigher$7Blower
Total debt$17.5Bhigher$5.3Blower
Cash on hand$17.9Bhigher$1.7Blower
Price change
Today-2.97%lower+0.76%higher
1 year+102%higher+70.1%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio. Who owns CNC · Who owns GMAB

Further comparisons

Learn

Questions and answers

Which is bigger, Centene or Genmab?

By market value, Centene is the larger: $35.9B against $32B for Genmab. By revenue in its latest fiscal year, Centene is the larger: $194.8B against $3.7B for Genmab.

Which has the higher P/E ratio?

Genmab: 44.4, against 24.9 for Centene. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Genmab: 28.6%, against -3.91% for Centene. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Centene: $17.5B, against $5.3B for Genmab. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Centene and Genmab?

None of the tracked superinvestors holds both in their latest 13F filing. 11 hold Centene and 1 holds Genmab.

Cite this page

Funkfolio, “Centene vs Genmab”, data as of 17 November 2026. https://funkfolio.com/compare/cnc-vs-gmab

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.